Role of surrogate end points in the evaluation of drugs for heart failure

Raymond John Lipicky, Milton Packer

Research output: Contribution to journalArticle

38 Citations (Scopus)

Abstract

To be of clinical value in the treatment of heart failure, a drug must permit patients either to feel better or to live longer, or both. Yet, because the assessment of both quality and quantity of life is difficult, many investigators have proposed using alternate measures (namely, surrogate end points) that may indicate the probable effect of a drag on symptoms or survival but are not direct measures of clinical benefit. Surrogate end points are usually physiologic variables that are known to be statistically associated and are believed to be pathophysiologically related to the clinical outcome. Although the adoption of such surrogate end points would dramatically facilitate the evaluation of new drugs, experience to date has shown that the effect of a drug on a surrogate end point is not a reliable predictor of the clinical utility of the drag, usually because the assumption that the end point is pathophysiologically related to the outcome proves to be invalid. Consequently, the evaluation of the effect of a drug on a surrogate end point provides us with a hypothesis rather than data about the possible effect of a drug on clinical events; such a hypothesis can be tested in controlled clinical trials that directly measure the clinical benefit of the therapeutic intervention. In the area of heart failure, no surrogate end point currently exists that can be used in lieu of the direct assessment of a drug on symptoms or survival, ideally in the context of a placebo-controlled trial.

Original languageEnglish (US)
JournalJournal of the American College of Cardiology
Volume22
Issue number4 SUPPL. 1
DOIs
StatePublished - 1993

Fingerprint

Drug Evaluation
Heart Failure
Biomarkers
Pharmaceutical Preparations
Survival
Controlled Clinical Trials
Treatment Failure
Placebos
Quality of Life
Research Personnel

ASJC Scopus subject areas

  • Nursing(all)

Cite this

Role of surrogate end points in the evaluation of drugs for heart failure. / Lipicky, Raymond John; Packer, Milton.

In: Journal of the American College of Cardiology, Vol. 22, No. 4 SUPPL. 1, 1993.

Research output: Contribution to journalArticle

Lipicky, Raymond John ; Packer, Milton. / Role of surrogate end points in the evaluation of drugs for heart failure. In: Journal of the American College of Cardiology. 1993 ; Vol. 22, No. 4 SUPPL. 1.
@article{ae0982c9d061496b8cc09f615ed1da6c,
title = "Role of surrogate end points in the evaluation of drugs for heart failure",
abstract = "To be of clinical value in the treatment of heart failure, a drug must permit patients either to feel better or to live longer, or both. Yet, because the assessment of both quality and quantity of life is difficult, many investigators have proposed using alternate measures (namely, surrogate end points) that may indicate the probable effect of a drag on symptoms or survival but are not direct measures of clinical benefit. Surrogate end points are usually physiologic variables that are known to be statistically associated and are believed to be pathophysiologically related to the clinical outcome. Although the adoption of such surrogate end points would dramatically facilitate the evaluation of new drugs, experience to date has shown that the effect of a drug on a surrogate end point is not a reliable predictor of the clinical utility of the drag, usually because the assumption that the end point is pathophysiologically related to the outcome proves to be invalid. Consequently, the evaluation of the effect of a drug on a surrogate end point provides us with a hypothesis rather than data about the possible effect of a drug on clinical events; such a hypothesis can be tested in controlled clinical trials that directly measure the clinical benefit of the therapeutic intervention. In the area of heart failure, no surrogate end point currently exists that can be used in lieu of the direct assessment of a drug on symptoms or survival, ideally in the context of a placebo-controlled trial.",
author = "Lipicky, {Raymond John} and Milton Packer",
year = "1993",
doi = "10.1016/0735-1097(93)90487-L",
language = "English (US)",
volume = "22",
journal = "Journal of the American College of Cardiology",
issn = "0735-1097",
publisher = "Elsevier USA",
number = "4 SUPPL. 1",

}

TY - JOUR

T1 - Role of surrogate end points in the evaluation of drugs for heart failure

AU - Lipicky, Raymond John

AU - Packer, Milton

PY - 1993

Y1 - 1993

N2 - To be of clinical value in the treatment of heart failure, a drug must permit patients either to feel better or to live longer, or both. Yet, because the assessment of both quality and quantity of life is difficult, many investigators have proposed using alternate measures (namely, surrogate end points) that may indicate the probable effect of a drag on symptoms or survival but are not direct measures of clinical benefit. Surrogate end points are usually physiologic variables that are known to be statistically associated and are believed to be pathophysiologically related to the clinical outcome. Although the adoption of such surrogate end points would dramatically facilitate the evaluation of new drugs, experience to date has shown that the effect of a drug on a surrogate end point is not a reliable predictor of the clinical utility of the drag, usually because the assumption that the end point is pathophysiologically related to the outcome proves to be invalid. Consequently, the evaluation of the effect of a drug on a surrogate end point provides us with a hypothesis rather than data about the possible effect of a drug on clinical events; such a hypothesis can be tested in controlled clinical trials that directly measure the clinical benefit of the therapeutic intervention. In the area of heart failure, no surrogate end point currently exists that can be used in lieu of the direct assessment of a drug on symptoms or survival, ideally in the context of a placebo-controlled trial.

AB - To be of clinical value in the treatment of heart failure, a drug must permit patients either to feel better or to live longer, or both. Yet, because the assessment of both quality and quantity of life is difficult, many investigators have proposed using alternate measures (namely, surrogate end points) that may indicate the probable effect of a drag on symptoms or survival but are not direct measures of clinical benefit. Surrogate end points are usually physiologic variables that are known to be statistically associated and are believed to be pathophysiologically related to the clinical outcome. Although the adoption of such surrogate end points would dramatically facilitate the evaluation of new drugs, experience to date has shown that the effect of a drug on a surrogate end point is not a reliable predictor of the clinical utility of the drag, usually because the assumption that the end point is pathophysiologically related to the outcome proves to be invalid. Consequently, the evaluation of the effect of a drug on a surrogate end point provides us with a hypothesis rather than data about the possible effect of a drug on clinical events; such a hypothesis can be tested in controlled clinical trials that directly measure the clinical benefit of the therapeutic intervention. In the area of heart failure, no surrogate end point currently exists that can be used in lieu of the direct assessment of a drug on symptoms or survival, ideally in the context of a placebo-controlled trial.

UR - http://www.scopus.com/inward/record.url?scp=0027362970&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027362970&partnerID=8YFLogxK

U2 - 10.1016/0735-1097(93)90487-L

DO - 10.1016/0735-1097(93)90487-L

M3 - Article

C2 - 8376690

AN - SCOPUS:0027362970

VL - 22

JO - Journal of the American College of Cardiology

JF - Journal of the American College of Cardiology

SN - 0735-1097

IS - 4 SUPPL. 1

ER -